These rules establish provisions for the permanent administration of the pharmaceutical representative licensing
program created by 2021 Senate Bill 763. Temporary rules were put in place in December of 2021 to facilitate
administration of the licensing program during calendar year 2022. These temporary rules will expire in June 2022.
The rules promulgate definitions to facilitate the administration of the program, define procedures for licensure
application and renewal, specify prohibited conduct and penalties for licensees, define expectations for the continuing education necessary to maintain licensure, define expectations for licensees to report information to DCBS, define procedures for the registration of education providers, define procedures for the registration of education courses, and define procedures for recording credit for continuing education.
Rules affected: OAR 836-200-0600, 836-200-0605, 836-200-0610, 836-200-0615, 836-200-0620, 836-200-0625, 836-200-0630, 836-200-0635, 836-200-0640, 836-200-0645, 836-200-0650, 836-200-0655, 836-200-0660, 836-200-0670
Filed: April 26, 2022
Public hearing:May 23, 2022, 11:00 a.m.,Online or conference call only due to COVID-19.
Microsoft Teams meeting:
Join on your computer or mobile app
Click here to join the meeting
Or call in (audio only)
+1 1 503-446-4951,,967652967#
United States, Portland
Phone Conference ID:
967 652 967#
Last day for public comment: May 27, 2022, 5 p.m.